Central Florida Cancer Care Center/Radiation Oncology Consultants Joins Statewide Practice
FORT MYERS, Fla., Sept. 1, 2023 /PRNewswire/ — Florida Cancer Specialists & Research Institute, LLC (FCS) Is pleased to announce that Central Florida Cancer Care Center/Radiation Oncology Consultants, PA has joined the statewide practice, effective September 1, 2023.
Nathan H. Walcker, FCS Chief Executive Officer, said, “Across Florida, we continue to add and enhance services so that patients can easily access world-class cancer treatment close to home. This partnership will provide many benefits for the Central Florida community, our patients and our clinic teams.”
Central Florida Cancer Care Center/Radiation Oncology Consultants Joins Florida Cancer Specialists & Research Institute. Board-certified radiation oncologists Maneesh Gossain, MD, Richard Lee, MD and Steven G. Lester, MD, FACRO, will continue to provide care to patients at two existing locations, renamed as FCS Orlando Radiation Oncology at 52 W. Gore Street, Orlando, FL 32806 and FCS Sanford Radiation Oncology at 2200 W. 1st Street, Sanford, FL 32771.
Board-certified radiation oncologists Maneesh Gossain, MD, Richard Lee, MD and Steven G. Lester, MD, FACRO will continue to provide care to patients at two existing locations, renamed as FCS Orlando Radiation Oncology at 52 W. Gore Street, Orlando, FL 32806 and FCS Sanford Radiation Oncology at 2200 W. 1st Street, Sanford, FL 32771.
“The size and scope of FCS will enable us to expand the range of sophisticated treatment therapies that are improving survival rates for many forms of cancer,” said Dr. Gossain. “Inhouse capabilities such as extensive next-generation testing and access to cutting-edge clinical trials will enhance our ability to develop personalized treatment plans that target each patient’s unique cancer.”
“These physicians have an extraordinary depth and breadth of experience in delivering evidence-based radiation oncology treatments and are equally well regarded for their compassion and concern for patients and their families,” said FCS President & Managing Physician Lucio N. Gordan, MD. “We are delighted to welcome them to FCS.”
Teams from the two practices have been working collaboratively in recent months to ensure a smooth transition with no disruption in patient care. “Treatment and care plans will remain consistent and uninterrupted,” said Dr. Lester.
About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com) Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with FCS participation.* Recognized for our research, FCS is a recipient of the national Clinical Trials Participation Award presented by the American Society of Clinical Oncology (ASCO). FCS physicians, trained in prestigious medical schools and research institutes, are consistently ranked nationally as Top Doctors by U.S. News & World Report.
Founded in 1984, FCS has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies genomic-based treatment and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.
SOURCE Florida Cancer Specialists & Research Institute
LOS ANGELES, Sept. 1, 2023 /PRNewswire/ — The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Eos Energy Enterprises, Inc. (“Eos” or the “Company”) (NASDAQ: EOSE).
Class Period: May 9, 2022 – July 27, 2023
Lead Plaintiff Deadline:October 2, 2023
If you are a shareholder who suffered a loss, click here to participate.
The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors: (1) that Bridgelink Commodities, LLC (“Bridgelink”) is connected to a group whose assets were seized by a creditor and sold in an auction; (2) that, as such, Bridgelink’s commitment and ability to purchase Eos products was not as secure as Eos had led investors to believe; (3) that, as such, Eos’s backlog was overstated; (4) that such overstatement negatively impacts Eos’s ability to secure a loan from the Department of Energy; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
SOURCE The Law Offices of Frank R. Cruz, Los Angeles
LOS ANGELES, Sept. 1, 2023 /PRNewswire/ — The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Live Nation Entertainment, Inc. (“Live Nation” or the “Company”) (NYSE: LYV).
Class Period: February 23, 2022 – July 28, 2023
Lead Plaintiff Deadline:October 3, 2023
If you are a shareholder who suffered a loss, click here to participate.
The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors: (1) that Live Nation engaged in anticompetitive conduct, including charging high fees and extended contracts with talent, and retaliated against venues; (2) that, as a result, Live Nation was reasonably likely to incur regulatory scrutiny and face fines, penalties, and reputational harm; and (3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
SOURCE The Law Offices of Frank R. Cruz, Los Angeles
LOS ANGELES, Sept. 1, 2023 /PRNewswire/ — The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Party City Holdco Inc. (“Party City” or the “Company”) (NYSE: PRTY; OTC: PRTYQ).
Class Period: November 8, 2022 – June 9, 2023
Lead Plaintiff Deadline:October 2, 2023
If you are a shareholder who suffered a loss, click here to participate.
The complaint filed alleges that, throughout the Class Period, Defendants: (1) affirmatively misrepresented that its capital resources “will be adequate to meet our liquidity needs for at least the next 12 months”; (2) omitted that there was substantial doubt about the Company’s ability to continue as a going concern; (3) downplayed the nature and extent of the Company’s then-existing liquidity problems; (4) omitted that the Company’s existing credit facilities were insufficient to satisfy its operational needs and that it was unable to obtain additional loans in the normal course of business; (5) omitted that there was a material weakness in its internal control over financial reporting; and (6) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
SOURCE The Law Offices of Frank R. Cruz, Los Angeles
LOS ANGELES, Sept. 1, 2023 /PRNewswire/ — Artrix, a pioneering solution provider of hardware, marketing supports, and strategy consultation in cannabis vape industry, today announced the highly-anticipated release of Drillor, their revolutionary 510 thread cart that promises to break through barriers and drive social equity in the cannabis vaping community. As part of their commitment to promoting fairness and inclusivity, Artrix is offering an unprecedented 100,000 units of Drillor for free to cannabis businesses and brands in need of support, as the start of theirSocial Equity Program.
Drillor offers a unique combination of industrial innovation and top-notch manufacturing capabilities, leading to an unprecedented shift in design and affordability. With a cutting-edge industrial design and craftsmanship, this innovation redefines what you thought you knew about 510 carts, daring to drill through the walls of stereotypes and conventional expectations.
The key feature that sets Drillor apart is its innovative mouthpiece. Designed with comfort and durability in mind, ensuring a pleasurable vaping experience with every use. Utilizing double injection molding and an oil-leakage-proof design, Drillor eliminates traditional rubber rings, reducing labor costs and providing worry-free installation. The exceptional mouthpiece, wrapped in liquid silicone material, offers a soft touch and easy grip, making vaping sessions enjoyable and stress-free.
An added convenience is the groundbreaking addition scale mark on the cartridge, enabling users to check the oil level at a glance. This attention to detail marries operation convenience with oil-filling accuracy, ensuring users bid farewell to overfilling and uncertainty, and instead enjoy a seamless, precise fill every time. The ergonomic grip of the plated brass anti-slip texture at the bottom ensures 510 cartridge removal is hassle-free, creating a comfortable and user-friendly experience.
“Drillor means affordable excellence and uncompromising safety. We believe that everyone should have access to high-quality vaping products regardless of their background or financial status,” said Chris Lin, CEO of Artrix. “With Drillor, we aim to level the playing field and make premium cannabis vaping accessible to all. Through our Social Equity Program, we want to empower cannabis businesses and brands, providing them with the tools to thrive and succeed.”
Artrix’s dedication to excellence and safety shines through in Drillor’s meticulous design and manufacturing process. From carefully selected raw materials to rigorous quality testing, each Drillor cartridge is crafted to ensure optimal vaping performance with various cannabis extracts, immersing users in a flavorful and satisfying experience with every puff.
As the first product project ofArtrix’s Social Equity Program, Drillor is a significant strategy taking a proactive step towards promoting social justice and inclusivity in the cannabis industry. By donating 100,000 units to cannabis businesses in need, Artrix aims to foster a more equitable and diverse future for the entire vaping community.
To claim your free Drillor 510 thread carts and be a part of the social equity movement, visit Artrix’s official websiteand register your interest today. Let’s work together to build a brighter, more inclusive future for the cannabis industry with Artrix leading the way.
About Artrix – Hardware, Marketing, Strategy, We’re All in.
Artrix is an emerging international cannabis vaporizer hardware brand that offers more than just cannabis vape devices. It uses an exclusive three-in-one service model that combines superior product solutions, systematic marketing support, and professional strategic consulting to create a great customer experience. Artrix conducts extensive market research and analysis to understand the needs behind each product and provides localized marketing support to maximize its market potential and success.
The global regulatory affairs outsourcing market is expected to witness impressive growth during the forecast period. This growth can be attributed to the increasing research and development (R&D) activities, the rising volume of clinical trial applications and product registrations, and the growing emphasis on regulatory compliance in the life sciences industry.
The complexity of regulatory frameworks in different regions, increasing globalization, and the need for specialized expertise have all contributed to the demand for regulatory affairs outsourcing services.
Key Drivers:
Research and Development Activities: The growth in R&D activities, especially in the pharmaceutical sector, is contributing to the demand for regulatory affairs outsourcing as companies seek specialized services to navigate regulatory complexities during drug development.
Regulatory Compliance: Governments and regulatory authorities are implementing stricter regulations to control drug costs. This has created economic and competitive pressure on life science companies, driving the demand for regulatory affairs outsourcing.
Trends and Opportunities:
Globalization Impact: As companies expand their operations globally, they face the challenge of complying with varying regulatory frameworks in different regions. This has led to the demand for regulatory affairs outsourcing services to navigate these complexities.
Expertise and Efficiency: Outsourcing regulatory affairs services provides companies with specialized expertise and resources, improving compliance, reducing costs, and allowing companies to focus on core competencies like product development and marketing.
Technological Advancements: The adoption of advanced technologies like AI, data analytics, and cloud-based systems has streamlined regulatory affairs processes, enabling faster and more accurate compliance activities.
Benefits of Outsourcing Regulatory Affairs:
Expertise: Regulatory affairs service providers offer specialized knowledge of diverse regulatory landscapes, helping companies comply with laws, regulations, and guidelines in different regions.
Cost Savings: Outsourcing provides cost-effective solutions compared to hiring and training in-house regulatory staff or using external consultants.
Specialized Focus: Outsourcing allows companies to concentrate on core activities while experts handle compliance, leading to improved operational efficiency.
Risk Reduction: Regulatory experts mitigate the risk of costly mistakes resulting from non-compliance, which could lead to product recalls or delays in approvals.
Companies Mentioned:
Accell Clinical Research, LLC.
Genpact Ltd.
CRITERIUM, INC.
Promedica International.
WuXi AppTec Co Ltd.
Medpace Inc.
Charles River Laboratories.
ICON plc.
Covance, Inc.
Parexel International Corporation.
Freyr AS
PHARMALEX GMBH
NDA Group AB
Pharmexon Consulting.
Qvigilance
BlueReg Group
Report Scope:
The report covers various segments of the global regulatory affairs outsourcing market, including services (regulatory consulting, legal representation, regulatory writing & publishing, product registration & clinical trial applications, regulatory submissions, regulatory operations, and other services), categories (pharmaceutical and medical device), company size (small, medium, and large companies), indication (oncology, neurology, cardiology, immunology, and others), product stage (preclinical, clinical, and premarket approval), end use (medical device, pharmaceutical, and biotechnology companies), and regions (North America, Europe, Asia-Pacific, South America, Middle East & Africa).
About ResearchAndMarkets.com ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
